| The Rab6 GTPase regulates recruitment of the dynactin complex to Golgi membranes B Short, C Preisinger, J Schaletzky, R Kopajtich, FA Barr Current Biology 12 (20), 1792-1795, 2002 | 254 | 2002 |
| Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatidylinositol 3-phosphatases J Schaletzky, SK Dove, B Short, O Lorenzo, MJ Clague, FA Barr Current biology 13 (6), 504-509, 2003 | 199 | 2003 |
| Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases AJ Russell, JJ Hartman, AC Hinken, AR Muci, R Kawas, L Driscoll, ... Nature medicine 18 (3), 452-455, 2012 | 147 | 2012 |
| Ribosome binding of a single copy of the SecY complex: implications for protein translocation JF Menetret, J Schaletzky, WM Clemons, AR Osborne, SS Skånland, ... Molecular cell 28 (6), 1083-1092, 2007 | 144 | 2007 |
| Determining the conductance of the SecY protein translocation channel for small molecules SM Saparov, K Erlandson, K Cannon, J Schaletzky, S Schulman, ... Molecular cell 26 (4), 501-509, 2007 | 142 | 2007 |
| SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA A Jack, LS Ferro, MJ Trnka, E Wehri, A Nadgir, X Nguyenla, D Fox, ... PLoS biology 19 (10), e3001425, 2021 | 109 | 2021 |
| Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy C Chuang, S Collibee, L Ashcraft, W Wang, M Vander Wal, X Wang, ... Journal of medicinal chemistry 64 (19), 14142-14152, 2021 | 95 | 2021 |
| Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection SB Biering, SA Sarnik, E Wang, JR Zengel, SR Leist, A Schäfer, ... Nature genetics 54 (8), 1078-1089, 2022 | 65 | 2022 |
| Ribosome binding to and dissociation from translocation sites of the endoplasmic reticulum membrane J Schaletzky, TA Rapoport Molecular biology of the cell 17 (9), 3860-3869, 2006 | 52 | 2006 |
| An intranasal ASO therapeutic targeting SARS-CoV-2 C Zhu, JY Lee, JZ Woo, L Xu, X Nguyenla, LH Yamashiro, F Ji, SB Biering, ... Nature communications 13 (1), 4503, 2022 | 43 | 2022 |
| Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis JM Hendricks, CE Doubravsky, E Wehri, Z Li, MA Roberts, KK Deol, ... Cell Chemical Biology 30 (9), 1090-1103. e7, 2023 | 28 | 2023 |
| Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator SE Collibee, G Bergnes, A Muci, WF Browne IV, M Garard, AC Hinken, ... ACS Medicinal Chemistry Letters 9 (4), 354-358, 2018 | 27 | 2018 |
| Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 SB Biering, E Van Dis, E Wehri, LH Yamashiro, X Nguyenla, ... ACS infectious diseases 7 (8), 2337-2351, 2021 | 25 | 2021 |
| Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells X Nguyenla, E Wehri, E Van Dis, SB Biering, LH Yamashiro, C Zhu, ... Scientific reports 12 (1), 18506, 2022 | 22 | 2022 |
| Discovery of reldesemtiv, a fast skeletal muscle troponin activator for the treatment of impaired muscle function SE Collibee, G Bergnes, C Chuang, L Ashcraft, J Gardina, M Garard, ... Journal of Medicinal Chemistry 64 (20), 14930-14941, 2021 | 14 | 2021 |
| Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy JJ Hartman, DT Hwee, J Wang, Y Wu, J Schaletzky, P Paliwal, K Lee, ... Biophysical Journal 118 (3), 596a, 2020 | 10 | 2020 |
| Pharmacologic characterization of the cardiac myosin inhibitor, CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy DT Hwee, JJ Hartman, J Wang, Y Wu, J Schaletzky, P Paliwal, K Lee, ... Circ. Res 125, A332, 2019 | 7 | 2019 |
| Getting a grip on microtubules J Schaletzky, M Rape Cell 164 (5), 836-837, 2016 | 7 | 2016 |
| Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design D Moussaoui, JP Robblee, D Auguin, F Fisher, PM Fagnant, ... bioRxiv, 2022.09. 09.507123, 2022 | 4 | 2022 |
| The class XIV myosin of Toxoplasma gondii, TgMyoA, is druggable in an animal model of infection A Kelsen, RS Kent, AK Snyder, E Wehri, SJ Bishop, RV Stadler, C Powell, ... bioRxiv, 2022.09. 09.507210, 2022 | 3 | 2022 |
